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Disclosure 
Evaluating albumin utilization in a community-based hospital post-hetastarch 
food and drug administration (FDA) warning 
Wilbert J. Fuerte, BS, Pharm.D., Frances Ordieres, Pharm.D., Judy Tseng, Pharm.D., BCPS 
South Miami Hospital, Miami, Florida 
Background 
 Albumin is a medication commonly used in the hospital setting. 
 
 The use of albumin is not justified in every clinical situation due to the 
lack of scientific evidence and the availability of other, equally effective 
medications.1,2 
 
 In June of 2012, the FDA released a warning regarding an increase in 
morbidity and mortality when hetastarch is used in several clinical 
settings.3 
 
 Because albumin and hetastarch are colloids, overlap exists in many of 
the indications of these two medications. Thus, it is expected that many 
prescribers will use albumin in place of  hetastarch in a variety of 
clinical scenarios. Consequently, an increase in albumin utilization and  
associated expenditure is expected. 
 
1. To identify albumin and hetastarch utilization. 
 
2. To evaluate if albumin is used for indications consistent with the 
recommendations from the American Thoracic Society (ATS) guidelines 
for the use of Colloids1 or the University Hospital Consortium (UHC) 
guidelines for the use of albumin, non-protein colloids, and 
crystalloids.2  
 
3. To determine if the new warning against the use of hetastarch3 has 
affected the prescribing pattern of albumin.  
 
4. To complete a cost analysis on albumin misuse. 
Methodology 
 
 
 Single-center, Baptist Health South Florida Institutional Review 
Board-approved, retrospective chart review. 
 
 Study Period: September of 2012 and September of 2013. 
 
 Inclusion Criteria: All patients 18 years of age and older during the 
study period  for which albumin and/or hetastarch were used. 
  
 Exclusion criteria: Anyone younger than 18 years of age or who did 
not use albumin or hetastarch during the study period.  
 
 A list containing the medical record number of patients for which 
either albumin and/or hetastarch was used during September of 2012 
and September of 2013 was  obtained from the pharmacy department 
system specialist.  
 
 Patients chart were reviewed in order to collect factors of different 
criteria described in the UHC and ATS guidelines for the appropriate 
utilization of albumin.  
 
 Pricing was obtained from the pharmacy department buyer for cost 
analysis.  
 
Data Analysis: 
 
 Descriptive statistics was completed for objectives 1, 2, and 3. 
 
 A Cost-Utility analysis was conducted for objective 4. 
 
 
Objectives 
Albumin Utilization 2012 Albumin Utilization 2013 
Surgery, 100% 
N = 4 
Hetastarch Utilization 2012 Hetastarch Utilization 2013 
*Others refer to indications observed in the study that are not mentioned in 
the UHC or ATS guidelines. 
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Indication 
Appropriate 
Innappropriate 
N = 39* 
 
¶Out of 20 patients, albumin was used after exhausting the use of 
substantial amounts (≥ 4 L) of crystalloids in only 5 patients.  
 
†Out of the two patients, one patient received albumin for  
hemodialysis-associated hypotension. The use of albumin is considered 
appropriate for this use according to the ATS guideline (IIa). The other 
patient received albumin 25% due to hemorrhagic hypovolemia secondary 
to rectal bleeding. Both the UHC and ATS guidelines state that crystalloids 
should be considered the initial resuscitation fluid of choice in this setting.  
 
‡Out of 4 patients, 2 patients received albumin 5 % which is not indicated in 
the setting of liver cirrhosis unless the patient has another indication for the 
medication according to either the UHC or ATS guideline. 
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Discussion 
 
 Albumin was utilized in a variety of clinical conditions, with septic shock 
being the most common reason for utilization (42.5 %, N = 20). 
 
 Based on the indications described in the UHC and ATS guidelines, 
albumin utilization during the time period described in this study was 
appropriately used only 20.5 % of the time.  
 
 Although albumin prescribing only increased by 10.3 % after the 
warning, the actual utilization of this medication increased by 47.4 %. 
On the other hand, hetastarch prescribing decreased by 83.9%, while 
the actual utilization of the medication decreased by 50 %.  
 
 Due to the significant increase in albumin utilization after the FDA 
warning, the total expenditure due to albumin utilization increased by 
39.0 %.  
 
 
 
 
 
 The use of albumin was considered inappropriate only if both 
guidelines  recommended against the use of albumin for the indication 
being analyzed. 
 
 The type of surgery was not recorded unless it was a liver or cardiac    
surgery.  
 
 The possibility of conditions precluding the use of normal saline were 
not considered for sepsis patients. 
 
 Small sample size and study duration. 
Limitations 
Conclusion 
 Although the data provided by this audit shows that prescribers are 
following the FDA recommendation of minimizing the use of hetastarch, 
it is concerning that albumin was appropriately utilized only 20.5 % of 
the time. Based on these findings, there is an opportunity for 
improvement in educating prescribers regarding the appropriate use of 
albumin in order to ensure proper utilization of this medication. 
 
 
*Out of 47 patients, 8 patients were administered albumin for an indication  
not mentioned in the UHC or ATS guidelines. Thus, it is not possible to 
evaluate the  utilization of albumin in this subset of patients. 
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